Generics

Taku Nakaoka is now chairman and CEO of Upsher-Smith and Rich Fisher, senior vice president of corporate strategy, is president and COO.

The medication is indicated as adjunctive therapy for adults and pediatric patients aged 2 years old and older with refractory complex partial seizures.

The medication is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and in pediatric patients.

Hikma now conservatively assumes it will launch its authorized generic on Jan. 1, 2023.

Enstilar foam had a market value of roughly $115.2 million for the 12-month period ending March 2022, according to IQVIA.

The company received approval for Iloperidone tablets and pregabalin capsules.

Docosanol cream 10% (OTC) had a market value of roughly $60 million for the 12 months ending December 2021, according to IQVIA.

The medication is the generic of progesterone injection, which is used to restore normal menstrual periods or treat abnormal bleeding due to low hormone levels.